resisttb
- Jan 19
- 1 min read

Price reduction paves the way for expanded access to highly effective MDR-TB

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.

Recent Posts

See All

John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test

“Why am I passionate about TB? It’s the deadliest disease in human history, but for most of human history we couldn’t do much about it. However, since the mid-1950s, TB has been curable — yet we still

Barely Contained Rage: An Open Letter to Danaher and Cepheid

"Danaher and Cepheid are using a printer-ink business model to overcharge for tuberculosis tests, thus resulting in millions of people going undiagnosed every year, many of whom will die." Watch the f

What’s new in the TB section of the 2023 WHO Model Lists of Essential Medicines

The World Health Organization’s (WHO’s) 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the tuberculosis (TB) section. These complement current WHO recommendat